There’s been an extraordinary acceleration of technologies in our business areas. Investing to keep pace with these changes, we’ve expanded our technology base in protein separations and increased our focus on molecular diagnostics in medical imaging. We've also built up our informatics capability, a key part of our enabling technologies as it helps make sense of the enormous amounts of data coming out of genomics, proteomics and molecular biology research. These moves strengthen our position in the global marketplace, underpinning future growth.

Our protein separations and medical diagnostics business areas are growing strongly and generating good revenues. We’re expanding manufacturing capacity in both these areas to meet market needs, and we’ll continue to invest in our core businesses to sustain their profitability in the short and long term. We’re now taking steps to bring discovery systems into profit, focusing on a smaller number of high-value systems and product lines.

We’ll obviously continue to manage our shareholders’ assets responsibly and transparently, following the rules of good corporate governance.